TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage biopharmaceutical company developing RNA-based therapeutics and immuno-oncology treatments for high-risk and advanced cancers, announced that its board of directors has initiated a formal strategic process to evaluate opportunities to maximize the value of the company and its oncology portfolio, including lead product candidate TTX-MC138. The review will consider potential licensing or sales of individual assets, development and commercialization partnerships, portfolio transactions, business combinations and other strategic alternatives. TransCode has engaged Tungsten Advisors as its exclusive strategic financial adviser for the process.
TTX-MC138, an investigational RNA-based therapeutic targeting microRNA-10b, has advanced into Phase 2a clinical development following a Phase 1a study that provided initial safety data and reports of stable disease. The ongoing trial is evaluating the treatment in patients with circulating tumor DNA-positive colorectal cancer following curative-intent therapy, in collaboration with Quantum Leap Healthcare Collaborative. TransCode also recently announced a collaboration with Natera Inc. to use its Signatera test to identify eligible patients and support trial enrollment.
Chairman and CEO Philippe P. Calais said the strategic review is intended to identify opportunities to advance the company’s oncology programs while seeking to maximize stockholder value. TransCode cautioned that the process may not result in a transaction or other strategic outcome.
The strategic review is a critical juncture for TransCode, as it seeks to unlock value from its pipeline of RNA therapeutics and immuno-oncology candidates. With TTX-MC138 in Phase 2a and additional first-in-class candidates designed to mobilize the immune system, the company is exploring ways to accelerate development and commercialization. The involvement of Tungsten Advisors suggests a thorough evaluation of options, which could include partnerships or out-licensing deals that provide non-dilutive funding. For investors, the outcome of this review could significantly impact the company’s trajectory, especially given the high-risk nature of oncology drug development. The recent collaborations with Quantum Leap and Natera underscore the potential of TTX-MC138 and the company’s efforts to strengthen its clinical position.
To view the full press release, visit https://ibn.fm/AGxas. The latest news and updates relating to RNAZ are available in the company’s newsroom at https://ibn.fm/RNAZ. For more information on BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences, visit BioMedWire. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which offers InvestorWire for wire solutions, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
